Catalyst Wire Dossier Catalyst Wire Dossier
CLINICAL_TRIALS trial_result · 2022-03-21

Clinical Trial Update: Clinical Trial Evaluating the Efficacy and Safety of Favipiravir in Moderate to Severe COVID-19 Patients [Phase 3]

View source ↗

Summary

Phase 3 trial evaluating favipiravir for moderate to severe COVID-19 was terminated; results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • Favipiravir (favipiravir)

Snippet

Sponsor: Dr. Reddy's Laboratories Limited | Conditions: Covid19 | Phase 3 | Status: TERMINATED | Results posted: 2022-03-21